Comparison of Antimycotic Activity of Originator and Generics of Voriconazole and Anidulafungin against Clinical Isolates of

C. albicans C. glabrata MIC TKC antifungals generic innovator

Journal

Journal of fungi (Basel, Switzerland)
ISSN: 2309-608X
Titre abrégé: J Fungi (Basel)
Pays: Switzerland
ID NLM: 101671827

Informations de publication

Date de publication:
17 Feb 2022
Historique:
received: 25 01 2022
revised: 15 02 2022
accepted: 16 02 2022
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

Concerns have been expressed about the interchangeability of innovator and generic antifungals in their activity and chemical stability. The activity of two different antimycotics was tested, each with one originator and two generics. For voriconazole, the originator VFEND MIC results showed no significant difference in activity of generic and innovator antimycotic in all settings, which was also confirmed by TKC. Stability testing revealed no differences between originator and generic drugs. The present study demonstrates the interchangeability of generic and originator antimycotic in-vitro, potentially leading to broader public acceptance for generic antimycotics.

Sections du résumé

BACKGROUND BACKGROUND
Concerns have been expressed about the interchangeability of innovator and generic antifungals in their activity and chemical stability.
MATERIALS/METHODS METHODS
The activity of two different antimycotics was tested, each with one originator and two generics. For voriconazole, the originator VFEND
RESULTS RESULTS
MIC results showed no significant difference in activity of generic and innovator antimycotic in all settings, which was also confirmed by TKC. Stability testing revealed no differences between originator and generic drugs.
CONCLUSIONS CONCLUSIONS
The present study demonstrates the interchangeability of generic and originator antimycotic in-vitro, potentially leading to broader public acceptance for generic antimycotics.

Identifiants

pubmed: 35205949
pii: jof8020195
doi: 10.3390/jof8020195
pmc: PMC8879245
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Clin Microbiol Infect. 2008 Apr;14(4):398-405
pubmed: 18190574
J Glob Antimicrob Resist. 2020 Dec;23:113-119
pubmed: 32890838
J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Feb 15;1139:121937
pubmed: 31958565
J Virus Erad. 2018 Apr 1;4(2):128-131
pubmed: 29682307
Antimicrob Agents Chemother. 2012 May;56(5):2659-65
pubmed: 22330928
Clin Pharmacol Ther. 2019 Feb;105(2):292-294
pubmed: 30460681
Br J Clin Pharmacol. 2009 Jul;68(1):34-42
pubmed: 19660001

Auteurs

Alina Karoline Nussbaumer-Pröll (AK)

Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.

Sabine Eberl (S)

Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.

René Welte (R)

Department of Clinical Pharmacokinetics, Innsbruck Medical University, 6020 Innsbruck, Austria.

Tiziana Gasperetti (T)

Department of Clinical Pharmacokinetics, Innsbruck Medical University, 6020 Innsbruck, Austria.

Jana Marx (J)

Department of Clinical Pharmacokinetics, Innsbruck Medical University, 6020 Innsbruck, Austria.

Romuald Bellmann (R)

Department of Clinical Pharmacokinetics, Innsbruck Medical University, 6020 Innsbruck, Austria.

Markus Zeitlinger (M)

Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.

Classifications MeSH